electroCore to Participate at H.C. Wainwright Global Investment Conference

electroCore, Inc. (Nasdaq: ECOR), a pioneering company in the field of bioelectronic medicine, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference, scheduled for September 9, 2025. The event will take place at the Lotte New York Palace Hotel, where members of electroCore’s management team will engage in one-on-one meetings throughout the day. Investors interested in scheduling a meeting are encouraged to contact their H.C. Wainwright sales representatives or reach out directly to electroCore’s Investor Relations at ecor@fnkir.com.

As a commercial-stage technology firm, electroCore is committed to enhancing health and quality of life through its innovative non-invasive bioelectronic solutions. The company’s flagship products, including the gammaCore non-invasive vagus nerve stimulation (nVNS) device and the Quell neurostimulator, focus on treating chronic pain syndromes through neuromodulation technology. These devices have been developed to provide patients with effective and non-invasive alternatives for pain management.

In addition to its prescription offerings, electroCore also markets handheld personal use devices, such as Truvaga and TAC-STIM, which are designed to leverage bioelectronic technologies to support general wellness and improve human performance. By combining cutting-edge technology with a focus on patient care, electroCore aims to establish itself as a leader in the bioelectronic medicine sector.

Investors and stakeholders can find more information about electroCore and its innovative product lineup by visiting the official website at www.electrocore.com, or by contacting the Investor Relations team at (973) 302-9253 or investors@electrocore.com. This conference appearance reflects electroCore’s ongoing efforts to engage with the investment community while showcasing its advancements and future potential in the healthcare industry.

As electroCore, Inc. (Nasdaq: ECOR) prepares for its participation in the H.C. Wainwright 27th Annual Global Investment Conference, investors should consider several critical factors that could influence their decision-making regarding the stock.

Firstly, electroCore operates in the burgeoning field of bioelectronic medicine, which presents significant growth potential in response to the increasing demand for non-invasive treatment options. The company’s flagship products, gammaCore and Quell, are aimed at addressing chronic pain syndromes, a market that is both large and under-served. With the global chronic pain market projected to grow significantly over the coming years, electroCore's strategic positioning could lead to substantial revenue growth.

Moreover, the upcoming conference represents an opportunity for management to showcase their innovations and strategic vision. Engaging directly with investors is a crucial step in enhancing transparency and building investor trust, particularly as the company seeks to expand its presence in both therapeutic and wellness markets. For investors, attending or following the conference could provide insights into the company’s pipeline, competitive advantages, and growth strategy.

It's also worth noting the company’s focus on expanding its product offerings, including the launch of Truvaga and TAC-STIM, which not only target chronic pain but promote overall wellness—a sector that has seen increasing consumer interest. This diversification could potentially reduce revenue volatility and improve market resilience.

However, as with any investment, potential risks must be considered, including regulatory challenges and competition. Investors must keep a close eye on the company's financial health and market conditions.

In conclusion, with a solid foothold in a growing industry and upcoming opportunities for engagement, electroCore presents an attractive opportunity for investors looking to tap into the future of bioelectronic medicine. Careful monitoring of developments following the conference will be essential for making informed investment decisions.